他莫昔芬作为早期乳腺癌治疗单一辅助药物的对照试验。“诺瓦得士”辅助治疗试验组织。
Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.
出版信息
Br J Cancer. 1988 Jun;57(6):608-11. doi: 10.1038/bjc.1988.138.
Abstract
At a maximum follow up of 8 years (median 5 years 6 months) in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxifen daily for 2 years. This advantage is independent of menopausal status, stage, grade and ER status. Log hazard rate analysis fails to demonstrate a rebound effect on stopping the drug and suggests that more prolonged treatment might further improve results.
摘要
在一项辅助性他莫昔芬与不治疗作为早期乳腺癌治疗方法的随机试验中，对患者进行了最长8年的随访（中位随访时间为5年6个月），结果显示，接受每日20毫克他莫昔芬治疗2年的患者仍具有显著优势。这一优势与绝经状态、分期、分级和雌激素受体状态无关。对数风险率分析未能证明停药后有反弹效应，提示延长治疗时间可能会进一步改善治疗效果。
相似文献
1
Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.他莫昔芬作为早期乳腺癌治疗单一辅助药物的对照试验。“诺瓦得士”辅助治疗试验组织。
Br J Cancer. 1988 Jun;57(6):608-11. doi: 10.1038/bjc.1988.138.
2
The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial.北约（“诺瓦得士”）试验中组织学分级、雌激素受体状态、事件及8年生存率之间的关系。
Br J Cancer. 1988 Jun;57(6):612-4. doi: 10.1038/bjc.1988.139.
3
4
5
6
7
Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial.
Breast Cancer Res Treat. 1986;7(2):105-9. doi: 10.1007/BF01806795.
8
The management of locally advanced carcinoma of the breast by Nolvadex (tamoxifen): a pilot study.
Clin Oncol. 1984 Jun;10(2):111-5.
9
The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer.
Eur J Surg Oncol. 1988 Jun;14(3):235-40.
10
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.他莫昔芬用于早期乳腺癌：随机试验综述。早期乳腺癌试验者协作组
Lancet. 1998 May 16;351(9114):1451-67.
引用本文的文献
1
Advancing equitable access to innovation in breast cancer.推进乳腺癌创新的公平可及性。
NPJ Breast Cancer. 2025 Jul 10;11(1):71. doi: 10.1038/s41523-025-00768-1.
2
How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?化疗后，如何为高危激素受体阳性、人表皮生长因子受体2阴性乳腺癌选择最佳辅助治疗方法？
Acta Oncol. 2025 Jun 25;64:815-829. doi: 10.2340/1651-226X.2025.43645.
3
Targeting LINC00152 activates cAMP/Ca/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.靶向LINC00152可激活cAMP/钙/铁死亡轴并克服雌激素受体阳性乳腺癌中的他莫昔芬耐药性。
bioRxiv. 2023 Nov 5:2023.11.05.565697. doi: 10.1101/2023.11.05.565697.
4
Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs.激素、靶向和联合疗法治疗乳腺癌：从人类到犬类。
Int J Mol Sci. 2024 Jan 5;25(2):732. doi: 10.3390/ijms25020732.
5
Systemic therapy for early-stage breast cancer: learning from the past to build the future.早期乳腺癌的系统性治疗：从过去中学习，为未来而建。
Nat Rev Clin Oncol. 2022 Dec;19(12):763-774. doi: 10.1038/s41571-022-00687-1. Epub 2022 Oct 17.
6
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.使用促黄体生成素释放激素激动剂抑制卵巢功能治疗绝经前激素受体阳性早期乳腺癌
Front Oncol. 2021 Sep 14;11:700722. doi: 10.3389/fonc.2021.700722. eCollection 2021.
7
Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.依西美坦，一种针对雌激素受体的靶向治疗药物：从基础研究到临床应用。
Endocrinology. 2021 Dec 1;162(12). doi: 10.1210/endocr/bqab191.
8
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.早期乳腺癌中延长辅助内分泌治疗的现状。
Curr Treat Options Oncol. 2018 Apr 27;19(5):26. doi: 10.1007/s11864-018-0541-1.
9
Endocrine Therapy for Early Breast Cancer: Updated Review.早期乳腺癌的内分泌治疗：最新综述
Ochsner J. 2017 Winter;17(4):405-411.
10
Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation.从失败的避孕药到畅销乳腺癌药物：他莫昔芬的药物创新案例研究
Front Pharmacol. 2017 Sep 12;8:620. doi: 10.3389/fphar.2017.00620. eCollection 2017.
本文引用的文献
1
2
Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7.抗雌激素他莫昔芬对人乳腺癌细胞系MCF-7细胞周期动力学的影响。
Br J Cancer. 1984 Jun;49(6):717-22. doi: 10.1038/bjc.1984.113.
3
British interlaboratory quality assessment of steroid receptor assays.英国类固醇受体检测的实验室间质量评估。
Recent Results Cancer Res. 1984;91:98-103. doi: 10.1007/978-3-642-82188-2_13.
4
Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase.他莫昔芬在激活环磷酸腺苷磷酸二酯酶过程中是一种钙调蛋白拮抗剂。
Biochem Biophys Res Commun. 1984 Jan 13;118(1):27-32. doi: 10.1016/0006-291x(84)91062-3.
5
Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor.使用对雌激素受体具有高亲和力的羟基三苯乙烯来定义抗雌激素对人乳腺癌细胞增殖的两种不同作用机制。
Biochem Biophys Res Commun. 1986 Oct 30;140(2):523-9. doi: 10.1016/0006-291x(86)90763-1.
6
Triphenylethylenes: a new class of protein kinase C inhibitors.
J Natl Cancer Inst. 1986 Jun;76(6):1243-6.
7
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.转化生长因子-β是人类乳腺癌细胞中一种受激素调节的负生长因子的证据。
Cell. 1987 Feb 13;48(3):417-28. doi: 10.1016/0092-8674(87)90193-0.
8
9
Measurement of oestradiol receptors by five institutions on common tissue samples.五个机构对常见组织样本进行雌二醇受体的测量。
Br J Cancer. 1978 Sep;38(3):428-30. doi: 10.1038/bjc.1978.224.
Zotero 插件